PDL trial (Genentech) in Global spots

[Catherine Poole]

I finally found out from Genentech that the only availability in this trial is for breast cancer. It was a multi-cancer trial with slots for different diseases. Best to stay in contact with those in UK and Europe/Australia who are running trials to see what is recruiting. They are the horse’s mouth and know best what is coming along. I do think approvals in US of PD1’s will transcribe to global but there is the difficulty of cost and approval by regulatory there as barriers.

[Gilly]

Do you mean the Roche MPDL3280A , Catherine ? The GO29322

2014-000812-33, NCT02174172 – it says inclusion for melanoma BUT I can’t find it anywhere in Europe – do you have any more info – Roche is not the most forthcoming !

[Catherine Poole]

I’m talking about the PDL trial by Genentech *)owned by Roche, NCT01375842. It only has openings for breast cancer and they must be triple negative patients. The one you mention is randomized with IPI and interferon. The one I hoped for is PDL alone.

[Author]

Posts